Regeneron Pharmaceuticals, Inc. (REGN) — Analyst outlook / Analyst consensus target is. Based on 48 analyst ratings, the consensus is bullish — 34 Buy, 14 Hold.
The consensus price target is $862.74 (low: $700.00, high: $1,057.00), representing an upside of 14.2% from the current price $755.51.
Analysts estimate Earnings Per Share (EPS) of $44.90 and revenue of $14.15B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $40.90 vs est $44.90 (missed -8.9%). 2025: actual $43.07 vs est $43.48 (missed -0.9%). Analyst accuracy: 95%.
REGN Stock — 12-Month Price Forecast
$862.74
▲ +14.19% Upside
Average Price Target
Based on 48 Wall Street analysts offering 12-month price targets for Regeneron Pharmaceuticals, Inc., the average price target is $862.74, with a high forecast of $1,057.00, and a low forecast of $700.00.
The average price target represents a +14.19% change from the last price of $755.51.
Highest Price Target
$1,057.00
Average Price Target
$862.74
Lowest Price Target
$700.00
REGN Analyst Ratings
Buy
Based on 48 analysts giving stock ratings to Regeneron Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — REGN
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $40.90
vs Est $44.90
▼ 9.8% off
2025
Actual $43.07
vs Est $43.48
▼ 1.0% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is improving.
Revenue Estimates — REGN
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $14.202B
vs Est $14.151B
▲ 0.4% off
2025
Actual $14.343B
vs Est $14.255B
▲ 0.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
